Search
  • mahroof m

NATCO Pharma launches epilepsy treatment drug Brivaracetam in India

NATCO pharma on Friday said it has launched epilepsy treatment drug 'Brivaracetam' in the country. The company has launched Brivaracetam tablets under brand BRECITA in India, Natco Pharma said in a regulatory filing. Brivaracetam, indicated towards the treatment of epilepsy, is developed by UCB Pharma and currently marketed in India by Dr Reddy's under the brand name Briviact. Natco Pharma said epilepsy patients in India are estimated to be between 5-10 million, as per GEMIND guidelines. Natco has launched BRECITA tablets in strengths of 50 mg and 100 mg priced at Rs 25 and Rs 35 per tablet, respectively.


Read more at: https://economictimes.indiatimes.com//industry/healthcare/biotech/pharmaceuticals/natco-pharma-launches-epilepsy-treatment-drug-brivaracetam-in-india/articleshow/81227179.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst


9 views0 comments

Recent Posts

See All

Novel discoveries in preventing epileptic seizures

A team of researchers from the Florida State University College of Medicine has found that an amino acid produced by the brain could play a crucial role in preventing a type of epileptic seizure. Temp